Gilead (GILD) CEO O'Day exercises options, sells 115,640 shares

Rhea-AI Filing Summary

Gilead Sciences Chairman and CEO Daniel P. O'Day reported an automatic option exercise and stock sale. On January 23, 2026, he exercised 115,640 non-qualified stock options at an exercise price of $66.01 per share, acquiring the same number of Gilead common shares. On the same day, he sold 115,640 common shares at a price of $135 per share. After these transactions, he directly owned 566,698 shares of Gilead common stock. The filing states that the transaction was carried out under a Rule 10b5-1 trading plan adopted on February 28, 2025, indicating it was pre-arranged under SEC rules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		M(1)		115,640	A	$66.01	682,338	D
Common Stock	01/23/2026		S(1)		115,640	D	$135	566,698	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)	$66.01	01/23/2026		M(1)			115,640	(2)	03/01/2029	Common Stock	115,640	$0	115,640	D

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

2. The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Daniel P. O'Day	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Gilead (GILD) CEO Daniel O'Day report in this Form 4?

Daniel P. O'Day reported exercising 115,640 non-qualified stock options at an exercise price of $66.01 per share and selling 115,640 common shares at $135 per share on January 23, 2026.

How many Gilead (GILD) shares does Daniel O'Day own after the reported transactions?

Following the reported sale, Daniel P. O'Day directly owned 566,698 shares of Gilead common stock.

Was the Gilead CEO’s stock sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

What type of derivative security did Daniel O'Day exercise in the Gilead Form 4?

He exercised a non-qualified stock option (right to buy) covering 115,640 shares of Gilead common stock at an exercise price of $66.01 per share.

What is the vesting schedule for Daniel O'Day’s Gilead stock options mentioned in the filing?

The stock options have a four-year vesting schedule: 25% vest on the first anniversary of the grant date, and the remaining balance vests 6.25% quarterly until fully vested.

What role does Daniel O'Day hold at Gilead Sciences (GILD)?

Daniel P. O'Day is reported as a Director and Officer of Gilead Sciences, serving as Chairman & CEO.